Endoglycosidase treatment abrogates IgG arthritogenicity: importance of IgG glycosylation in arthritisVise andre og tillknytning
2007 (engelsk)Inngår i: European Journal of Immunology, ISSN 0014-2980, E-ISSN 1521-4141, Vol. 37, nr 10, s. 2973-2982Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]
The glycosylation status of IgG has been implicated in the pathology of rheumatoid arthritis. Earlier, we reported the identification of a novel secreted endo-beta-N-acetylglucosaminidase (EndoS), secreted by Streptococcus pyogenes that specifically hydrolyzes the beta-1,4-di-N-acetylchitobiose core of the asparagine-linked glycan of human IgG. Here, we analyzed the arthritogenicity of EndoS-treated collagen type II (CII)-specific mouse mAb in vivo. Endoglycosidase treatment of the antibodies inhibited the induction of arthritis in (BALB/c x B10.Q) F1 mice and induced a milder arthritis in B10.RIII mice as compared with the severe arthritis induced by non-treated antibodies. Furthermore, EndoS treatment did not affect the binding of IgG to CII and their ability to activate complement, but it resulted in reduced IgG binding to FcgammaR and disturbed the formation of stable immune complexes. Hence, the asparagine-linked glycan on IgG plays a crucial role in the development of arthritis. © 2007 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.
sted, utgiver, år, opplag, sider
Weinheim: Wiley-VCH Verlagsgesellschaft, 2007. Vol. 37, nr 10, s. 2973-2982
Emneord [en]
Arthritis, EndoS, IgG
HSV kategori
Identifikatorer
URN: urn:nbn:se:hh:diva-48837DOI: 10.1002/eji.200737581ISI: 000250294100031PubMedID: 17899548Scopus ID: 2-s2.0-35348875440OAI: oai:DiVA.org:hh-48837DiVA, id: diva2:1719040
2022-12-142022-12-142023-02-16bibliografisk kontrollert